Tom 5, Nr 1-2 (2024)
Artykuł przeglądowy
Opublikowany online: 2024-10-10
Wyświetlenia strony
86
Wyświetlenia/pobrania artykułu
41
Rzadkie choroby limfoproliferacyjne ujęte w 5. wersji klasyfikacji WHO
1
DOI: 10.5603/hemedu.98900
Hematologia — Edukacja 2024;5(1-2):44-54.
Streszczenie
Artykuł poświęcono nowo wyłonionej grupie chorób limfoproliferacyjnych, uwzględnionej w 5. klasyfikacji WHO. To zagadnienia medyczne z pogranicza obszaru specjalizacji hematologa. Dotyczą głównie chorób rzadkich oraz tych, których diagnozą i leczeniem zajmują się głównie specjaliści reumatolodzy. Pomimo braku charakteru klonalnego opisywanych limfoproliferacji, ich przebieg kliniczny może być agresywny, wymagając szybkiego wprowadzenia specjalistycznej terapii. Przede wszystkim jednak wyzwaniem pozostaje szybka i precyzyjna diagnoza. W artykule przedstawiono cechy kliniczne i laboratoryjne poszczególnych jednostek chorobowych, dokonano także przeglądu metod ich leczenia.
Słowa kluczowe: choroba Castlemanachoroby IgG4-zależnechoroby limfoproliferacyjne
Referencje
- Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022; 36(7): 1720–1748.
- Dispenzieri A, Fajgenbaum DC. Overview of Castleman disease. Blood. 2020; 135(16): 1353–1364.
- Mukherjee S, Martin R, Sande B, et al. Epidemiology and treatment patterns of idiopathic multicentric Castleman disease in the era of IL-6-directed therapy. Blood Adv. 2022; 6(2): 359–367.
- Dunn R, Jariwal R, Venter F, et al. HHV-8-associated multicentric Castleman disease, a diagnostic challenge in a patient with acquired immunodeficiency syndrome and fever. J Investig Med High Impact Case Rep. 2022; 10: 23247096221097526.
- Chang KC, Wang YC, Hung LY, et al. Monoclonality and cytogenetic abnormalities in hyaline vascular Castleman disease. Mod Pathol. 2014; 27(6): 823–831.
- Singh KI, Gollapudi S, Kumar J, et al. Case report: Castleman disease with an associated stromal spindle cell proliferation, PDGFRB mutation and p53 expression: clonal origins of a rare disease. Front Oncol. 2022; 12: 857606.
- Fajgenbaum DC, Uldrick TS, Bagg A, et al. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood. 2017; 129(12): 1646–1657.
- van Rhee F, Voorhees P, Dispenzieri A, et al. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood. 2017; 129(12): 1646–1657.
- Mukherjee S, Martin R, Sande B, et al. Epidemiology and treatment patterns of idiopathic multicentric Castleman disease in the era of IL-6-directed therapy. Blood Adv. 2022; 6(2): 359–367.
- Nishimura Y, Fajgenbaum DC, Pierson SK, et al. Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease. Am J Hematol. 2021; 96(10): 1241–1252.
- Ahuja K, Goudar R. Castleman disease: a population based study using the national cancer institute's surveillance, epidemiology, and end results program. Blood. 2022; 140(Supplement 1): 12114–12115.
- Mukherjee S, Kanhai K, Kauffman D, et al. Organ dysfunction, thrombotic events and malignancies in patients with idiopathic multicentric castleman disease: a population-level US health claims analysis. Leukemia. 2022; 36(10): 2539–2543.
- Molacek J, Treska V, Skalicky T, et al. Unicentric form of Castleman´s disease, pitfalls of diagnosis and surgical treatment. Front Oncol. 2023; 13: 1057683.
- González García A, Fernández-Martín J, Robles Marhuenda Á. Idiopathic multicentric Castleman disease and associated autoimmune and autoinflammatory conditions: practical guidance for diagnosis. Rheumatology (Oxford). 2023; 62(4): 1426–1435.
- Talat N, Belgaumkar AP, Schulte KM. Surgery in Castleman's disease: a systematic review of 404 published cases. Ann Surg. 2012; 255(4): 677–684.
- Sitenga J, Aird G, Ahmed A, et al. Impact of siltuximab on patient-related outcomes in multicentric Castleman's disease. Patient Relat Outcome Meas. 2018; 9: 35–41.
- Rasmussen C, Gérard L, Fadlallah J, et al. Higher rate of progression in HIV– than in HIV+ patients after rituximab for HHV8+ multicentric Castleman disease. Blood Adv. 2023; 7(18): 5663–5669.
- Oksenhendler E, Boutboul D, Fajgenbaum D, et al. The full spectrum of Castleman disease: 273 patients studied over 20 years. Br J Haematol. 2018; 180(2): 206–216.
- Giannopoulos K, Jamroziak K, Usnarska-Zubkiewicz L, et al. Zalecenia Polskiej Grupy Szpiczakowej dotyczące rozpoznawania i leczenia szpiczaka plazmocytowego oraz innych dyskrazji plazmocytowych na rok 2022/23. Polska Grupa Szpiczakowa.
- van Rhee F, Rosenthal A, Kanhai K, et al. Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease. Blood Adv. 2022; 6(16): 4773–4781.
- Pierson SK, Katz L, Williams R, et al. CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease. Nat Commun. 2022; 13(1): 7236.
- Innoue D, Yoshida K, Yoneda N, et al. IgG4-related disease: dataset of 235 consecutive patients. Medicine (Baltimore). 2015; 94(15): e680.
- Wallace ZS, Deshpande V, Mattoo H, et al. IgG4-related disease: clinical and laboratory features in one hundred twenty-five patients. Arthritis Rheumatol. 2015; 67(9): 2466–2475.
- Katz G, Stone JH. Clinical perspectives on IgG4-related disease and its classification. Annu Rev Med. 2022; 73: 545–562.
- Zhang W, Stone JH. Management of IgG4-related disease. Lancet Rheumatol. 2019; 1(1): e55–e65.
- Wallwork R, Perugino CA, Fu X, et al. The association of smoking with immunoglobulin G4-related disease: a case-control study. Rheumatology (Oxford). 2021; 60(11): 5310–5317.
- Wallace Z, Naden R, Chari S, et al. The 2019 American College of Rheumatology/European League Against Rheumatism Classification criteria for IgG4‐related disease. Arthritis & Rheumatology. 2019; 72(1): 7–19.
- Wallace Z, Mattoo H, Carruthers M, et al. Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations. Annals of the Rheumatic Diseases. 2014; 74(1): 190–195.
- Choi SuJ, Ahn SM, Oh JiS, et al. Serum IgG4 level during initial treatment as a predictor of relapse in IgG4-related disease. PLoS One. 2023; 18(3): e0282852.
- Culver E, Sadler R, Bateman A, et al. Increases in igE, eosinophils, and mast cells can be used in diagnosis and to predict relapse of igg4-related disease. Clin Gastroenterol Hepatol. 2017; 15(9): 1444–1452.e6.
- Yu T, Wu Y, Liu J, et al. The risk of malignancy in patients with IgG4-related disease: a systematic review and meta-analysis. Arthritis Res Ther. 2022; 24(1): 14.
- Zongfei Ji, Lingli C, Ying S, et al. Clinical and pathological predictors of relapse in IgG4-related disease. Arthritis Res Ther. 2022; 24(1): 106.
- Yue Z, Tong F, Chen Y. Risk factors for IgG4‐related disease relapse: a systematic review and meta‐analysis. Scand J Immunol. 2022; 96(3): e13200.
- Zhang W, Stone J. Management of IgG4-related disease. Lancet Rheumatol. 2019; 1(1): e55–e65.
- Dojcinov S, Fend F, Quintanilla-Martinez L. EBV-positive lymphoproliferations of B- T- and NK-cell derivation in non-immunocompromised hosts. Pathogens. 2018; 7(1): 28.
- Arai A. Chronic active Epstein–Barr virus infection: the elucidation of the pathophysiology and the development of therapeutic methods. Microorganisms. 2021; 9(1): 180.
- Kimura H, Cohen JI. Chronic active Epstein-Barr virus disease. Front Immunol. 2017; 8: 1867.
- Kawa K, Sawada A, Sato M, et al. Excellent outcome of allogeneic hematopoietic SCT with reduced-intensity conditioning for the treatment of chronic active EBV infection. Bone Marrow Transplant. 2011; 46(1): 77–83.
- Slack GW. The pathology of reactive lymphadenopathies: a discussion of common reactive patterns and their malignant mimics. Arch Pathol Lab Med. 2016; 140(9): 881–892.
- Hicks J, Flaitz C. Progressive transformation of germinal centers: review of histopathologic and clinical features. Int J Pediatr Otorhinolaryngol. 2002; 65(3): 195–202.
- Shaikh F, Ngan B, Alexander S, et al. Progressive transformation of germinal centers in children and adolescents: An intriguing cause of lymphadenopathy. Pediatr Blood Cancer. 2012; 60(1): 26–30.
- Grigg A, Ganju V. PET positive progressive transformation of germinal centers masquerading as relapsed Hodgkin lymphoma post-autograft. Leuk Lymphoma. 2006; 47(4): 764–765.
- Wills C, Mercer K, Malysz J, et al. Chronic generalized lymphadenopathy in a child — progressive transformation of germinal centers (PTGC). Children. 2022; 9(2): 214.
- Papachristodoulou E, Graef E, Magliulo D, et al. Prevalence and clinical significance of lymphadenopathy and its histological subtypes in patients with systemic lupus erythematosus: a retrospective cohort study. Rheumatol Int. 2023; 43(7): 1277–1286.
- Vázquez-Meraz J, Duarte-Salazar C, Franco-Cendejas R, et al. Generalized lymphadenopathy as an atypical initial clinical manifestation in rheumatoid arthritis and a possible hypothetical mechanism. Discussion of Clinical Cases. 2022; 9(1): 13–17.
- Abba AA, Khalil M. Clinical approach to Lymphadenopathy. Ann of Nigerian Med. 2012; 6(1): 11.
- Li Pu, Huang P, Yang Ye, et al. Updated understanding of autoimmune lymphoproliferative syndrome (ALPS). Clin Rev Allergy Immunol. 2016; 50(1): 55–63.
- Lambert MP. Presentation and diagnosis of autoimmune lymphoproliferative syndrome (ALPS). Expert Rev Clin Immunol. 2021; 17(11): 1163–1173.
- Hafezi N, Zaki‐Dizaji M, Nirouei M, et al. Clinical, immunological, and genetic features in 780 patients with autoimmune lymphoproliferative syndrome (ALPS) and ALPS‐like diseases: A systematic review. Pediatr Allergy Immunol. 2021; 32(7): 1519–1532.
- Laville D, Martin L, Chauleur C, et al. Florid lymphoid hyperplasia or lymphoma-like lesion of the lower genital tract: a 35-year literature review in view of the new WHO classification. Int J Gynecol Pathol. 2022; 41(5): 459–469.
- Pai T, Menon S, Deodhar K, et al. Florid reactive lymphoid hyperplasia (lymphoma-like lesion) of cervix: A diagnostically challenging case and a brief review of literature. J Cancer Res Ther. 2015; 11(4): 1035.
